Invivyd (IVVD) announced the June 20, 2025 updated National Comprehensive Cancer Network, NCCN, Clinical Practice Guidelines in Oncology for the Prevention and Treatment of Cancer-Related Infections now recommend the use of available monoclonal antibodies for pre-exposure prophylaxis of COVID-19. The NCCN Guidelines advise clinicians to refer to guidance from Infectious Diseases Society of America, IDSA, Centers for Disease Control and Prevention, CDC, or U.S. Food and Drug Administration for available monoclonal antibody options. This recommendation reflects the growing alignment among key organizations – including IDSA and CDC – reinforcing the critical role of monoclonal antibodies in protecting immunocompromised individuals from COVID-19.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVVD:
- Invivyd Launches SPEAR Study for Long COVID Therapy
- Invivyd forms SPEAR study group to assess therapy for long-COVID
- Invivyd’s VYD2311: Promising Phase 1/2 Trial Results and Strategic Positioning Support Buy Rating
- Invivyd Announces Positive Phase 1/2 Trial Results
- Invivyd announces full Phase 1/2 clinical data for VYD2311